InsidersTradesSigma
Follow the X4 Pharmaceuticals, Inc stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, X4 Pharmaceuticals, Inc has recorded 138 reports. Market capitalisation: €425.3m. The latest transaction was disclosed on 13 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Ragan Paula. Every trade is free.
138
Insider Decl.
n/a
Thresholds
€258,425
4 ops.
Buy Volume
€1m
65 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate X4 Pharmaceuticals, Inc Strong Buy (bullish), based on 5 analysts. Average price target: US$11.60.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,055 of 29,062 companies
28.6
score / 100
Value10
Quality47
FCF yld-22%
Earn yld-20%
EV/EBITDA·
ROE-113%
Gross mgn84%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 August 2026
Declarations138 total
47,436 shares@ US$4.555Common StockSEC144:0001339498-26-000003
24,576 shares@ US$4.555Common StockSEC144:0002081729-26-000004
47,436 shares@ US$4.44450.050% mcap45.9% of flowCommon StockSEC:0001501697-26-000069:0
24,576 shares@ US$4.44450.026% mcap100.0% of flowCommon StockSEC:0001501697-26-000070:0
86,206 shares@ US$2.90100.0% of flowCommon StockSEC:0001501697-25-000035:0
Canonical exit: 21 Jan 2026 (T+90)
289,881 shares0Common StockSEC:0001628280-25-040444:0
289,881 shares0Common StockSEC:0001628280-25-040441:0
193,254 shares0Common StockSEC:0001628280-25-040440:0
3,333 shares0Common StockSEC:0001628280-25-034233:0
1,500 shares0Common StockSEC:0001628280-25-030504:0
1,500 shares0Common StockSEC:0001628280-25-030503:0
1,500 shares0Common StockSEC:0001628280-25-030502:0
1,500 shares0Common StockSEC:0001628280-25-030500:0
1,500 shares0Common StockSEC:0001628280-25-030492:0
1,500 shares0Common StockSEC:0001628280-25-030489:0
1,032 shares@ US$2.4827.4% of flowCommon StockSEC:0001628280-25-029113:0
1,032 shares@ US$2.4828.0% of flowCommon StockSEC:0001628280-25-026864:0
Canonical exit: 14 Aug 2025 (T+90)
21,646 shares@ US$0.67746.9% of flowCommon StockSEC:0001628280-25-005698:0
Canonical exit: 15 Aug 2024 (T+90)
650,000 shares0Common StockSEC:0001628280-25-005696:0
850,000 shares0Common StockSEC:0001628280-25-005702:0
2,250,000 shares0Common StockSEC:0001628280-25-005700:0
850,000 shares0Common StockSEC:0001628280-25-005704:0
25,831 shares0Common StockSEC:0001628280-25-002705:0
74,773 shares0Common StockSEC:0001628280-25-002707:0
169,940 shares0Common StockSEC:0001628280-25-002709:0
25 of 138 declarations
关于 X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc. 是一家在美国纳斯达克（XFOR）上市的美国生物制药公司，专注于开发和商业化与CXCR4生物学相关的罕见免疫系统和血液疾病的创新疗法。公司总部位于马萨诸塞州波士顿。其根源可追溯到以CXCR4为重点的科学平台以及与赛诺菲/健赞的许可基础，并通过与Arsanis的合并以及随后对高未满足需求的罕见疾病项目的重新聚焦，塑造了现代公司。X4成立于2014年。（[investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-completes-merger-arsanis/?utm_source=openai)） X4的主要资产是mavorixafor，一种口服选择性CXCR4拮抗剂。该药物在美国以XOLREMDI®的名称销售，用于治疗WHIM综合征，一种罕见的原发性免疫缺陷。这使得X4不仅仅是一个纯粹的临床阶段故事：它已进入部分商业化的生物制药模式，尽管公司的价值仍然高度集中于单一主要资产。管理层还表示，正在进行针对慢性中性粒细胞减少症的关键性3期4WARD试验，该试验得到了FDA授予mavorixafor治疗慢性中性粒细胞减少症的快速通道资格的支持。（[investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2025?utm_source=openai)） 从竞争角度来看，X4是一家专业公司，而非广泛平台的制药公司。其差异化来自于CXCR4生物学及其对治疗选择有限的罕见疾病的关注，如果开发成功，这可以支持有意义的临床和商业独占性。与此同时，这种集中也带来了高执行风险：投资案例过度依赖监管里程碑、XOLREMDI的采用以及公司关键临床项目的结果。X4此前曾探索过其他CXCR4项目，包括肿瘤学和临床前计划，但已将其重点缩小，以最大化其核心资产的价值。（[investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-strategic-restructuring-drive-value?utm_source=openai)） 最近的发展强调了这一战略。在其2026年第一季度更新中，X4表示其首要任务仍然是执行和全面招募关键的4WARD研究，并指出净产品销售主要由XOLREMDI的美国销售驱动。在2026年初，公司还报告了2025年全年业绩和公司更新，重申其故事围绕罕见血液学和持续的开发进展。对于讲法语的投资者来说，X4应被视为一家在美国纳斯达克上市的专业小型生物技术公司，拥有集中的产品线、在罕见疾病领域的商业立足点，以及其估值可能仍然高度受临床、监管和上市执行里程碑影响。（[investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-first-quarter-2026-financial-results?utm_source=openai)）
